Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 13.04.2026 1 Am J Surg 1 Ann Oncol 1 Ann Surg 3 Ann Surg Oncol 5 BMC Cancer 4 Br J Cancer 5 Breast Cancer 1 Breast Cancer (Auckl) 3 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 1 Breast Cancer Res Treat 2 Breast J 3 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Cancer Res 1 Clin Breast Cancer 1 Clin Cancer Res 3 Histopathology 1 Int J Oncol 1 J Clin Oncol 1 J Natl Cancer Inst 1 J Pathol 3 JAMA 1 Lancet Oncol 5 NPJ Breast Cancer 1 Oncogene 1 PLoS Comput Biol 4 PLoS One 2 Radiol Artif Intell 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg

1. BARMETTLER G, Kohlbeck S, Cortina CS, Kantor O, et al
   Experiences and challenges of sexual and gender minority patients undergoing breast cancer treatment.
   Am J Surg. 2026;257:116947.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. DENT R, Shao Z, Schmid P, Cortes J, et al
   Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
   Ann Oncol. 2026 Apr 3:S0923-7534(26)00130-4. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   

   
   Ann Surg

3. JOLISSAINT JS, Lobaugh SM, Goldman DA, McIntyre SM, et al
   Frequency and Natural History of Emergency General Surgery Conditions in Cancer Patients: A SEER-medicare Population Analysis.
   Ann Surg. 2026;283:783-790.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. CHEN JH, Wanis KN, Rahman M, Gianchandani A, et al
   Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.
   Ann Surg Oncol. 2026 Apr 8. doi: 10.1245/s10434-026-19588.
   PubMed         Abstract available
   
   
5. MONTAGNA G, Weber WP, Morrow M, Sevilimedu V, et al
   Letter to the Editor Regarding Abdulla, H.A., et al. "Oncologic Outcomes of Sentinel Lymph Node Biopsy Versus Targeted Axillary Dissection for Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review and Meta-analysis".
   Ann Surg Oncol. 2026 Apr 5. doi: 10.1245/s10434-026-19602.
   PubMed        
   
   
6. BOCCARDO F
   ASO Author Reflections: LYMPHA for Prevention of Breast Cancer-Related Lymphedema: Long-Term Evidence from a 15-Year Follow-Up.
   Ann Surg Oncol. 2026 Apr 5. doi: 10.1245/s10434-026-19596.
   PubMed        
   
   

   
   BMC Cancer

7. QI WX, Ou D, Cao L, Li S, et al
   The PRINCE-BC trial: precision regional irradiation of nodal stations for clinical evaluation of high-risk pN0 breast cancer - a phase III, open-label, randomized controlled trial.
   BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15971.
   PubMed        
   
   
8. ANSARI H, Hajigholami A, Aslani H, Hajigholami A, et al
   Preliminary modeling of brain metastases in breast cancer: a neural network approach to risk factor analysis.
   BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15954.
   PubMed        
   
   
9. NISHIKAWA M, Kashiwagi S, Kochi A, Watanabe C, et al
   Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.
   BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15913.
   PubMed        
   
   
10. BARJIJ I, Lamsyah O, Kdadri S, Lkhoyaali S, et al
    Spatial and temporal intratumoral heterogeneity in breast cancer: a systematic and conceptual review of single-cell and spatial omics studies.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15928.
    PubMed        
    
    
11. TADA M, Kikawa Y, Shibata N, Hirai C, et al
    Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15962.
    PubMed         Abstract available
    
    

    
    Br J Cancer

12. FIGUEROA V, Coianis MI, Sahores A, Pataccini G, et al
    Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer.
    Br J Cancer. 2026 Apr 4. doi: 10.1038/s41416-026-03420.
    PubMed         Abstract available
    
    
13. AZAM S, Lamb LR, Eliassen AH, King TA, et al
    Performance of an image-only deep learning breast cancer risk model with the addition of a polygenic risk score.
    Br J Cancer. 2026 Apr 6. doi: 10.1038/s41416-026-03415.
    PubMed         Abstract available
    
    
14. POUGOUE KETCHEMEN J, Monzer A, Njotu FN, Babeker H, et al
    Potency and safety of novel [(225)Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer.
    Br J Cancer. 2026 Apr 7. doi: 10.1038/s41416-026-03393.
    PubMed         Abstract available
    
    
15. WANG Z, Ingebriktsen LM, Bekkhus T, Ma L, et al
    Podoplanin-defined tumour plasticity and CCR7-mediated lymphatic metastasis in triple-negative breast cancer.
    Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03402.
    PubMed         Abstract available
    
    

    
    Breast Cancer

16. CHAUHAN K, Kumari P, Devi D, Thakur S, et al
    Niraparib in breast cancer: evidence-based perspective on translational progress.
    Breast Cancer. 2026 Apr 7. doi: 10.1007/s12282-026-01856.
    PubMed        
    
    
17. MANTRIPRAGADA A, Vaughn S, Ganti L
    Fear of diagnosis as a barrier to the screening and diagnosis of breast cancer.
    Breast Cancer. 2026 Apr 7. doi: 10.1007/s12282-026-01845.
    PubMed        
    
    
18. IWAMOTO N, Horiguchi SI, Kuwayama T, Toi M, et al
    Low-progesterone receptor expression predicts nodal pathological complete response after neoadjuvant chemotherapy in premenopausal patients with ER-positive/HER2-negative breast cancer.
    Breast Cancer. 2026 Apr 7. doi: 10.1007/s12282-026-01851.
    PubMed        
    
    
19. ABE M, Morita K, Konishi T, Nara K, et al
    Factors associated with central venous port implantation during breast cancer perioperative chemotherapy: a Japanese database study.
    Breast Cancer. 2026 Apr 7. doi: 10.1007/s12282-026-01850.
    PubMed        
    
    
20. SAKAI T, Kimura Y, Ishitobi M, Yoshida A, et al
    Changes in re-excision rates after publication of guidelines defining positive margins for breast-conserving surgery: a collaborative study of the Japanese breast cancer society.
    Breast Cancer. 2026 Apr 8. doi: 10.1007/s12282-026-01853.
    PubMed        
    
    

    
    Breast Cancer (Auckl)

21. LIANG W, Wang ZY, Shao QF, Li YY, et al
    Genes From Epithelial-Mesenchymal Transition Predict Overall Survival Effectively in Breast Cancer: A Novel Risk Model Based on Initial Step of Tumor Metastasis.
    Breast Cancer (Auckl). 2026;20:11782234261433697.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

22. GONG X, Zhang D, Wen Z, Zeng J, et al
    Lipid Metabolism and Breast Cancer Therapy: An Integrative Literature Review.
    Breast Cancer (Dove Med Press). 2026;18:575419.
    PubMed         Abstract available
    
    
23. CHEN HH, Chang SJ, Kan JY, Chen FM, et al
    Prognostic Value of Ki-67 and Progesterone Receptor for Risk Stratification and Outcomes by Adjuvant Chemotherapy in Early Luminal-Type Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:597707.
    PubMed         Abstract available
    
    
24. LIAO X, Wu X, Zheng J, Lin G, et al
    Discrimination of Triple-Negative Breast Cancer: A Robust Clinical Baseline versus Multimodal Magnetic Resonance Imaging Integrated Models with Assessment of Generalizability.
    Breast Cancer (Dove Med Press). 2026;18:594356.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

25. ZIRPOLI G, Pfeiffer RM, Palmer JR
    Performance of three breast cancer risk assessment tools in US Black women.
    Breast Cancer Res. 2026 Apr 9. doi: 10.1186/s13058-026-02274.
    PubMed        
    
    
26. SHIN SH, Ahn SG, Ryu JM, Lee SB, et al
    Contributing factors of contralateral breast cancer in patients with BRCA mutation (ON-BRCA II study, KoREa-BSG 11).
    Breast Cancer Res. 2026 Apr 9. doi: 10.1186/s13058-026-02273.
    PubMed         Abstract available
    
    
27. SILVESTRI V, Valentini V, Bucalo A, Porzio V, et al
    Transcriptomic deconvolution reveals prognostic immune signatures and immunotherapy-responsive subtypes in male breast cancer.
    Breast Cancer Res. 2026 Apr 7. doi: 10.1186/s13058-026-02236.
    PubMed        
    
    
28. DU L, Zhu L, Yang Y, Pan L, et al
    TTPAL inhibits the progression of breast cancer and reprograms tumor-associated macrophages by inhibiting JAK2/STAT3 signaling pathway.
    Breast Cancer Res. 2026 Apr 5. doi: 10.1186/s13058-026-02246.
    PubMed        
    
    
29. LI Z, Su H, Xiao H, Chen C, et al
    Integrating tumor habitat heterogeneity with a hybrid deep learning architecture for ultrasound radiomics: a dual-center study on non-invasive prediction of PD-L1 expression in triple-negative breast cancer.
    Breast Cancer Res. 2026 Apr 4. doi: 10.1186/s13058-026-02275.
    PubMed        
    
    

    
    Breast Cancer Res Treat

30. FADELU TA, Odai-Afotey A, Martin A, Skeffington M, et al
    The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:11.
    PubMed         Abstract available
    
    

    
    Breast J

31. OBAID LN, Zhang JS, Lee GY, Bhimani F, et al
    The Impact of Socioeconomic Factors and Racial Disparities on Complications in Breast Conservation Surgery: A Single-Institution Retrospective Cohort Study.
    Breast J. 2026;2026:e8459253.
    PubMed         Abstract available
    
    
32. HATZIPANAGIOTOU ME, Tannert V, Gerken M, Pigerl M, et al
    Treatment Regimens and Response Rates in Early TNBC: A Review of Real-World Practice in the Second Decade of the 21st Century.
    Breast J. 2026;2026:e9970072.
    PubMed         Abstract available
    
    

    
    Cancer

33. KISHIMOTO K, Nakata K, Kato MS, Ikawa T, et al
    Increasing incidence and changing distribution of primary cancers in therapy-related acute myeloid leukemia: A population-based study in Osaka, Japan, 1990-2020.
    Cancer. 2026;132:e70316.
    PubMed         Abstract available
    
    
34. LAWRENCE L
    T-DXd shows benefit over T-DM1 in patients with early breast cancer.
    Cancer. 2026;132:e70330.
    PubMed        
    
    
35. LAWRENCE L
    Adding carboplatin to adjuvant chemotherapy improved survival in early-stage triple-negative breast cancer.
    Cancer. 2026;132:e70331.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

36. ALTUNDAG K
    Timing of dose reduction matters: interpreting survival outcomes with CDK4/6 inhibitors in advanced breast cancer.
    Cancer Chemother Pharmacol. 2026;96:31.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

37. PEHRSSON M, Jakkula E, Ala-Kulju K, Loukola A, et al
    Opportunistic screening of high breast cancer risk variants in hospital biobank setting.
    Cancer Epidemiol Biomarkers Prev. 2026 Apr 9. doi: 10.1158/1055-9965.EPI-25-1757
    PubMed         Abstract available
    
    

    
    Cancer Lett

38. SABIT H, Yadav AK, Salimy S, Sakr A, et al
    Integrating Multi-Omics and Artificial Intelligence for Personalized Breast Cancer Management: A Guide to Clinicians.
    Cancer Lett. 2026 Apr 3:218468. doi: 10.1016/j.canlet.2026.218468.
    PubMed         Abstract available
    
    

    
    Cancer Res

39. WONG H, Korsakova A, Wu AJ, Kularatnarajah L, et al
    An Analytical Framework Characterizes the Biological Processes that Shape Copy Number-Based Genome Instability Patterns in Breast Cancer.
    Cancer Res. 2026 Apr 9. doi: 10.1158/0008-5472.CAN-25-2569.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

40. LAD N, Blocker S, Monson T, Grauer D, et al
    Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer.
    Clin Breast Cancer. 2026;26:57-62.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

41. JHAVERI K, Eli LD, Hurvitz SA, Brufsky A, et al
    Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.
    Clin Cancer Res. 2026 Apr 6. doi: 10.1158/1078-0432.CCR-25-4135.
    PubMed         Abstract available
    
    

    
    Histopathology

42. PANG JB, Gorringe KL, Tan PH, Fox SB, et al
    Molecular pathology of phyllodes tumours of the breast-much more than MED12.
    Histopathology. 2026;88:1115-1125.
    PubMed         Abstract available
    
    
43. INGYIN H, Solomon JP, Li Y, Xu D, et al
    Genetic and immunohistochemical studies identify recurrent ACTB mutations and PTEN alterations in tubular adenomas of the breast.
    Histopathology. 2026;88:1229-1235.
    PubMed         Abstract available
    
    
44. KRINGS G, Hashem S, Apushkin MA, Ang-Rabanes TL, et al
    Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.
    Histopathology. 2026;88:1212-1220.
    PubMed         Abstract available
    
    

    
    Int J Oncol

45. LIANG Y, Besch-Williford C, Hyder SM
    [Corrigendum] PRIMA?1 inhibits growth of breast cancer cells by re?activating mutant p53 protein.
    Int J Oncol. 2026;68:68.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

46. CATHCART-RAKE EJ, Thao V, Le-Rademacher J, Helfinstine DA, et al
    Nationwide Mammographic Screening Among a Large Population of Underserved Subgroups.
    J Clin Oncol. 2026;44:981-991.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

47. JAYASEKERA J, Hooshmand S, Strassle PD, Schneider J, et al
    Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019.
    J Natl Cancer Inst. 2026 Apr 3:djag103. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Pathol

48. HIPOLITO A, Abreu B, Goncalves J, Silva F, et al
    Fatty acid and cysteine metabolic interplay regulate ferroptosis and highlight xCT as a selenium-chrysin target in breast carcinoma.
    J Pathol. 2026;269:34-54.
    PubMed         Abstract available
    
    

    
    JAMA

49. SMIT F, Kaufman JS, Chiolero A
    Screening for Breast Cancer.
    JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1266.
    PubMed        
    
    
50. PESAPANE F, Cassano E
    Screening for Breast Cancer.
    JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1263.
    PubMed        
    
    
51. ESSERMAN LJ, Olopade OI, Eklund M
    Screening for Breast Cancer-Reply.
    JAMA. 2026 Apr 6. doi: 10.1001/jama.2026.1269.
    PubMed        
    
    

    
    Lancet Oncol

52. PROWSE J
    European Breast Cancer Conference 2026.
    Lancet Oncol. 2026 Apr 2:S1470-2045(26)00173.
    PubMed        
    
    

    
    NPJ Breast Cancer

53. ZHAO Q, Li N, Marinovic E, McInerny S, et al
    Investigating the contribution of rare non-coding variants in BRCA1, BRCA2 and PALB2 to hereditary breast cancer.
    NPJ Breast Cancer. 2026 Apr 4. doi: 10.1038/s41523-026-00942.
    PubMed         Abstract available
    
    
54. TRUONG TH, Gillis NE, Dwyer AR, Huggins RJ, et al
    Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutation.
    NPJ Breast Cancer. 2026 Apr 7. doi: 10.1038/s41523-026-00939.
    PubMed         Abstract available
    
    
55. FARROKHI P, Park L, Schmutz HW, Thompson SL, et al
    Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States.
    NPJ Breast Cancer. 2026 Apr 8. doi: 10.1038/s41523-026-00945.
    PubMed         Abstract available
    
    
56. EGLE D, Hlauschek D, Gampenrieder SP, Rinnerthaler G, et al
    Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial.
    NPJ Breast Cancer. 2026 Apr 8. doi: 10.1038/s41523-026-00934.
    PubMed         Abstract available
    
    
57. FINNE K, Kjolle S, Romero MR, Birkeland E, et al
    Stromal-based proteome data improve stratification of hormone receptor-positive breast cancer.
    NPJ Breast Cancer. 2026 Apr 9. doi: 10.1038/s41523-026-00943.
    PubMed         Abstract available
    
    

    
    Oncogene

58. CHEN H, Hu X, Feng L, Cheng X, et al
    PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment.
    Oncogene. 2026 Apr 7. doi: 10.1038/s41388-026-03753.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

59. DAVYDZENKA K, Caravagna G, Sanguinetti G
    Extending differential gene expression testing to handle genome aneuploidy in cancer.
    PLoS Comput Biol. 2026;22:e1014134.
    PubMed         Abstract available
    
    

    
    PLoS One

60. LYU J, Wang E, Lyu S, Qian Y, et al
    JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis.
    PLoS One. 2026;21:e0341313.
    PubMed         Abstract available
    
    
61. AKRAM L, Abbas G, Khurram H, Aslam A, et al
    Association of marital and parental status with stress, support, adherence, and quality of life among breast cancer women.
    PLoS One. 2026;21:e0346016.
    PubMed         Abstract available
    
    
62. 
    Retraction: 3, 3'-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells.
    PLoS One. 2026;21:e0346218.
    PubMed        
    
    
63. YANG J, Qu S, Qi X, Liu Y, et al
    The PD-1 and CD28 molecules on T cells in peripheral blood are associated with the prognosis of patients with advanced breast cancer receiving paclitaxel chemotherapy.
    PLoS One. 2026;21:e0344366.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

64. ZHOU LQ, Wang XY, Xu Y, Zhang HX, et al
    Radiopathomic Graph Deep Learning for Multiscale Spatial-Contextual Modeling of Intratumoral Heterogeneity to Predict Breast Cancer Response to Neoadjuvant Therapy.
    Radiol Artif Intell. 2026 Apr 8:e250760. doi: 10.1148/ryai.250760.
    PubMed         Abstract available
    
    
65. ZHAO C, Dong Y, Xie X, Wu G, et al
    Clinic-aligned Dual Distillation of Video and Image Foundation Models for Automated Breast Cancer US Diagnosis.
    Radiol Artif Intell. 2026 Apr 8:e250600. doi: 10.1148/ryai.250600.
    PubMed         Abstract available
    
    

    
    Radiother Oncol

66. BECHERINI C, Blondeaux E, Delucchi V, Visani L, et al
    Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.
    Radiother Oncol. 2026;219:111523.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum